谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.

Marcelo Vailati Negrao,Maria Pia Morelli,Amir A. Jazaeri,Benny Johnson,Partow Kebriaei, Drew Deninger,Eleanor De Groot,Matthew R. Collinson-Pautz,Nathan A. Demars,Jaymes S. Holland,John Heymach,Raffaele Baffa,Scott Kopetz

Journal of Clinical Oncology（2022）

引用 1|浏览23
暂无评分
关键词
advanced solid tumors,tcrs,first-in-human,t-cell,cancer-specific
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要